SYNLOGIC, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
SYNLOGIC, INC. (SYBX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $99.00 million as of 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2018-08-09
- 2018-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $99.00M.
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $86.30M.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $19.30M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2018-06-30 | $99.00M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $86.30M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $19.30M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |